Pharmacotherapeutic management of psoriasis in adolescents and children

References

• Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386(9997):983–994.
   PubMed Web of Science ®Google Scholar
• Tollefson MM, Crowson CS, McEvoy MT, et al. Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol. 2010;62(6):979–987.
   PubMed Web of Science ®Google Scholar
• Silverberg NB. Update on pediatric psoriasis. Cutis. 2015;95(3):147–152.
   PubMed Web of Science ®Google Scholar
• Augustin M, Glaeske G, Radtke MA, et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162(3):633–636.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Wu EQ, Guerin A, et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol. 2012;67(4):651–657 e1–e2.
   Web of Science ®Google Scholar
• Talamonti M, Galluzzo M, Servoli S, et al. Alexithymia and plaque psoriasis: preliminary investigation in a clinical sample of 250 patients. Dermatology. 2016;232(6):648–654.
   PubMed Web of Science ®Google Scholar
• Farber EM, Mullen RH, Jacobs AH, et al. Infantile psoriasis: a follow-up study. Pediatr Dermatol. 1986;3:237–243.
   PubMedGoogle Scholar
• Chiam LY, de Jager ME, Giam YC, et al. Juvenile psoriasis in European and Asian children: similarities and differences. Br J Dermatol. 2011;164(5):1101–1103.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP, Gross J. A comparative study of pediatric onset psoriasis with adult onset psoriasis. Pediatr Dermatol. 2000;17(3):174–178.
   PubMed Web of Science ®Google Scholar
• Sanclemente G, Murphy R, Contreras J, et al. Anti-TNF agents for paediatric psoriasis. Cochrane Database Syst Rev. 2015;11:CD010017.
   PubMed Web of Science ®Google Scholar
• Bhutani T, Kamangar F, Cordoro KM. Management of pediatric psoriasis. Pediatr Ann. 2012;41(1):e1–7.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Paller AS, Tom WL, et al. Pediatric psoriasis: evolving perspectives. Pediatr Dermatol. 2018;35(2):170–181.
   PubMed Web of Science ®Google Scholar
• Thomas J, Parimalam K. Treating pediatric plaque psoriasis: challenges and solutions. Pediatric Health Med Ther. 2016;7:25–38.
   PubMed Web of Science ®Google Scholar
• de Jager ME, de Jong EM, van de Kerkhof PC, et al. Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol. 2010;62(6):1013–1030.
   PubMed Web of Science ®Google Scholar
• Tollefson MM. Diagnosis and management of psoriasis in children. Pediatr Clin North Am. 2014;61(2):261–277.
   PubMed Web of Science ®Google Scholar
• Herz G, Blum G, Yawalkar S. Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis. J Am Acad Dermatol. 1991;25:1166–1169.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Gold MH, Zib B, et al. Clobetasol propionate emulsion formulation foam phase IIICSG. Clobetasol propionate emulsion formulation foam 0.05 %: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents. J Am Acad Dermatol. 2008;59(3):448–54 (54 e1).
   Web of Science ®Google Scholar
• Darley CR, Cunliffe WJ, Green CM, et al. Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris. Br J Dermatol. 1996;135(3):390–393.
   PubMed Web of Science ®Google Scholar
• Oranje AP, Marcoux D, Svensson A, et al. Topical calcipotriol in childhood psoriasis. J Am Acad Dermatol. 1997;36:203–208.
   PubMed Web of Science ®Google Scholar
• Liao YH, Chiu HC, Tseng YS, et al. Comparison of cutaneous tolerance and efficacy of calcitriol 3 μg g−1 ointment and tacrolimus 0⋅3 mg g−1 ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Br J Dermatol. 2007;157(5):1005–1012.
   PubMed Web of Science ®Google Scholar
• van Geel MJ, Mul K, Oostveen AM, et al. Calcipotriol/betamethasone dipropionate ointment in mild-to-moderate paediatric psoriasis: long-term daily clinical practice data in a prospective cohort. Br J Dermatol. 2014;171:363–369.
   PubMed Web of Science ®Google Scholar
• Van de Kerkhof PC, Hoffmann V, Anstey A, et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol. 2009;160(1):170–176.
   PubMed Web of Science ®Google Scholar
• Oostveen AM, de Jong EM, Donders AR, et al. Treatment of paediatric scalp psoriasis with calcipotriene/betamethasone dipropionate scalp formulation: effectiveness, safety and influence on children’s quality of life in daily practice.J. Eur Acad Dermatol Venereol. 2015;29:1193–1197.
   PubMed Web of Science ®Google Scholar
• Gooderham M, Debarre JM, Keddy-Grant J, et al. Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12– 17 years of age. Br J Dermatol. 2014;171:1470–1477.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Siskin SB, Epinette W, et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol. 1996;35(2 Pt 1):268–269.
   PubMed Web of Science ®Google Scholar
• Kin KC, Hill D, Feldman SR. Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis. Expert Rev Clin Pharmacol. 2016;9(6):789–797.
   PubMed Web of Science ®Google Scholar
• Brouda I, Edison B, Van Cott A, et al. Tolerability and cosmetic acceptability of liquor carbonis distillate (coal tar) solution 15% as topical therapy for plaque psoriasis. Cutis. 2010;85(4):214–220.
   PubMed Web of Science ®Google Scholar
• Pittelkow MR, Perry HO, Muller SA, et al. Skin cancer in patients with psoriasis treated with coal tar. A 25-year follow-up study. Arch Dermatol. 1981;117(8):465–468.
   PubMedGoogle Scholar
• Roelofzen JH, Aben KK, Oldenhof UT, et al. No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema. J Invest Dermatol. 2010;130(4):953–961.
   PubMed Web of Science ®Google Scholar
• Reichert U, Jacques Y, Grangeret M, et al. Antirespiratory and antiproliferative activity of anthralin in cultured human keratinocytes. J Invest Dermatol. 1985;84(2):130–134.
   PubMed Web of Science ®Google Scholar
• Guerrier CJ, Porter DI. An open assessment of 0.1% dithranol in a 17% urea base (’Psoradrate’ 0.1%) in the treatment of psoriasis of children. Curr Med Res Opin. 1983;8(6):446–450.
   PubMed Web of Science ®Google Scholar
• Zvulunov A, Anisfeld A, Metzker A. Efficacy of short-contact therapy with dithranol in childhood psoriasis. Int J Dermatol. 1994;33(11):808–810.
   PubMedGoogle Scholar
• de Jager ME, van de Kerkhof PC, de Jong EM, et al. Dithranol therapy in childhood psoriasis: unjustifiably on the verge of falling into oblivion. Dermatology. 2010;220:329–332.
   PubMed Web of Science ®Google Scholar
• Oostveen AM, Beulens CA, van de Kerkhof PC, et al. The effectiveness and safety of short-contact dithranol therapy in paediatric psoriasis: a prospective comparison of regular day care and day care with telemedicine. Br J Dermatol. 2014;170:454–457.
   PubMed Web of Science ®Google Scholar
• Oostveen AM, de Jager ME, van de Kerkhof PC, et al. The influence of treatments in daily clinical practice on the Children’s Dermatology Life Quality Index in juvenile psoriasis: a longitudinal study from the Child-CAPTURE patient registry. Br J Dermatol. 2012;167:145–149.
   PubMed Web of Science ®Google Scholar
• Wang C, Lin A. Efficacy of topical calcineurin inhibitors in psoriasis. J Cutan Med Surg. 2014;18(1):8–14.
   PubMed Web of Science ®Google Scholar
• Brune A, Miller DW, Lin P, et al. Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr Dermatol. 2007;24(1):76–80.
   PubMed Web of Science ®Google Scholar
• Steele JA, Choi C, Kwong PC. Topical tacrolimus in the treatment of inverse psoriasis in children. J Am Acad Dermatol. 2005;53(4):713–716.
   PubMed Web of Science ®Google Scholar
• Mahé E. Childhood psoriasis. Eur J Dermatol. 2016;26:14–18.
   Web of Science ®Google Scholar
• Relvas M, Torres T. Pediatric psoriasis. Am J Clin Dermatol. 2017;18:797–811.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Megna M, Balato A, et al. Systemic treatment of pediatric psoriasis: a review. Dermatol Ther (Heidelb). 2016;6:125–142.
   PubMed Web of Science ®Google Scholar
• Crall CS, Rork JF, Delano S, et al. Phototherapy in children: considerations and indications. Clin Dermatol. 2016;34:633–639.
   PubMed Web of Science ®Google Scholar
• Pinson R, Sotoodian B, Fiorillo L. Psoriasis in children. Psoriasis Targets Ther. 2016;6:121–129.
   PubMedGoogle Scholar
• Bronckers IMGJ, Paller AS, van Geel MJ, et al. Psoriasis in children and adolescents: diagnosis, management and comorbidities. Pediatr Drugs. 2015;17:373–384.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Paller AS, Tom WL, et al. Pediatric psoriasis: evolving perspectives. Pediatr Dermatol. 2018;35:170–181.
   Web of Science ®Google Scholar
• Fortina AB, Bardazzi F, Berti S, et al. Treatment of severe psoriasis in children: recommendations of an Italian expert group. Eur J Pediatr. 2017. DOI:10.1007/s00431-017-2985-x.
   Web of Science ®Google Scholar
• Subedi S, Yu Q, Chen Z, et al. Management of pediatric psoriasis with acitretin: a review. Dermatol Ther. 2017;1–6. DOI:10.1111/dth.12571
   Web of Science ®Google Scholar
• Chen P, Li C, Xue R, et al. Efficacy and safety of acitretin monotherapy in children with pustular psoriasis: results from 15 cases and a literature review. J Dermatolog Treat. 2018;29:353–363.
   PubMed Web of Science ®Google Scholar
• van Geel MJ, Mul K, de Jager ME, et al. Systemic treatments in paediatric psoriasis: a systematic evidence-based update. J Eur Acad Dermatol Venereol. 2015 Mar;29(3):425-437.
   Google Scholar
• Fortina AB, Bardazzi F, Berti S, et al. Treatment of severe psoriasis in children: recommendations of an Italian expert group. Eur J Pediatr. 2017;176(10):1339–1354.
   PubMed Web of Science ®Google Scholar
• Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358(3):241–251.
   PubMed Web of Science ®Google Scholar
• [cited Mar 2019]. Available from: https://www.ema.europa.eu/en/documents/variation-report/enbrel-h-c-262-ii-134-epar-assessment-report-variation_en.pdf
   Google Scholar
• Paller AS, Siegfried EC, Pariser DM, et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol. 2016;74(2):280–287.e1.
   PubMed Web of Science ®Google Scholar
• [cited Mar 2019]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/humira
   Google Scholar
• Papp K, Thaci D, Marcoux D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomized, double-blind, phase 3 trial. Lancet. 2017;390:40–49.
   PubMed Web of Science ®Google Scholar
• Tsang V, Dvorakova V, Enright F, et al. Successful use of infliximab as first line treatment for severe childhood generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2016;30:e1117–e1119.
   Web of Science ®Google Scholar
• Dixit S, Shumack S, Fischer G. Ustekinumab in the treatment of severe paediatric psoriasis. Aust J Dermatol. 2013;54:147.
   PubMed Web of Science ®Google Scholar
• AbuHilal M, Ho N. Successful treatment of severe psoriasis in an adolescent with ustekinumab. Pediatr Dermatol. 2015;32:377–380.
   PubMed Web of Science ®Google Scholar
• Fotiadu C, Lazaridou E, Giannopoulou D. Ustekinumab for the treatment of an adolescent patient with recalcitrant plaque psoriasis. Eur J Dermatol. 2011;21:117–118.
   PubMed Web of Science ®Google Scholar
• Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594–603.
   PubMed Web of Science ®Google Scholar
• Wells LE, Evans T, Hilton R, et al. Use of secukinumab in a pediatric patient leads to significant improvement in nail psoriasis and psoriatic arthritis. Pediatr Dermatol. 2019;36:384–385. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Natsis NE, Steixner J, Gottlie. Success of the IL-17 inhibitor ixekizumab in a case of refractory pediatric psoriasis and a summary of fda-approved biologics for moderate to severe pediatric psoriasis vulgaris. J Psoriasis Psoriatic Arthritis. 2018;4(1):11–14.
   Google Scholar
• Lu Y, Kane S, Chen H, et al. The role of 39 psoriasis risk variants on age of psoriasis onset. ISRN Dermatol. 2013;2013:203941.
   PubMedGoogle Scholar
• Zhang L, Li Y, Yang X, et al. Characterization of Th17 and FoxP3(+) Treg cells in paediatric psoriasis patients. Scand J Immunol. 2016;83(3):174–180.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yang XQ, Cheng J, et al. Increased Th17 cells are accompanied by FoxP3(+) Treg cell accumulation and correlated with psoriasis disease severity. Clin Immunol. 2010;135:108–117.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Talamonti M, D’Adamio S, et al. Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis. Expert Opin Drug Metab Toxicol. 2017 Jun;13(6):679–691.
   PubMed Web of Science ®Google Scholar
• Cordoro KM, Hitraya-Low M, Taravati K, et al. Skin-infiltrating, interleukin-22-producing T cells differentiate pediatric psoriasis from adult psoriasis. J Am Acad Dermatol. 2017;77(3):417–424.
   PubMed Web of Science ®Google Scholar
• Carrier Y, Ma HL, Ramon HE, et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol. 2011;131(12):2428–2437.
   PubMed Web of Science ®Google Scholar
• Cordoro KM, Ucmak D, Hitraya-Low M, et al. Response to Interleukin (IL)-17 inhibition in an adolescent with severe manifestations of IL-36 receptor antagonist deficiency (DITRA). JAMA Dermatol. 2017;153(1):106–108.
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals. pediatric study in children and adolescents with severe plaque. psoriasis. [cited Mar 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT02471144. NLM Identifer: NCT02471444
   Google Scholar
• Eli Lilly and Company. Study of Ixekizumab (LY2439821) in children 6 to less than 18 years with moderate-to-severe plaque psoriasis (Ixora-peds). [cited Mar 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT03073200. NLM Identifier: NCT03073200
   Google Scholar
• Kaushik SB, Lebwohl MG. CME part II psoriasis: which therapy for which patient focus on special populations and chronic infections. JAAD. 2019;80(1):43–53.
   PubMed Web of Science ®Google Scholar
• Clark RA. Gone but not forgotten: lesional memory in psoriatic skin. J Invest Dermatol. 2011 Feb;131(2):283–285.
   PubMed Web of Science ®Google Scholar
• Park CO, Kupper TS. The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nat Med. 2015 Jul;21(7):688–697.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Massarotti E, Garg R, et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011 Jun 22;305(24):2525–2531.
   PubMed Web of Science ®Google Scholar